メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
藤原 稚也
医学部・内科学（第２）
h-index
613
被引用数
8
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2003
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(25)
類似のプロファイル
(6)
フィンガープリント
Wakaya Fujiwaraが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
On-site Assessment
42%
Angiography-derived Fractional Flow Reserve
42%
Invasive Fractional Flow Reserve
42%
Omecamtiv Mecarbil
42%
Myosin Activation
42%
Acute Kidney Injury
42%
Elderly Patients with Heart Failure
42%
Cardiac Intensive Care Unit
42%
Electrocardiographic Diagnosis
42%
Fatty
42%
MiR-126
42%
Tissue Tracking
42%
Liver Type
42%
Velocity Pattern
42%
Left Atrial Function
42%
Transmitral Flow
42%
Pseudonormalization
42%
Thiazide Diuretics
42%
Heart Failure Severity
42%
Non-valvular Atrial Fibrillation
42%
Prescription Pattern
42%
Elderly Hypertension
42%
Hydrochlorothiazide
42%
Rosuvastatin
42%
Adverse Outcomes
42%
Azilsartan
42%
Glucose Profile
42%
Urinary Liver-type Fatty Acid Binding Protein
42%
Novel Oral Anticoagulants
42%
Oral Anticoagulants
42%
Creatinine
33%
Resistin
31%
Candesartan
31%
Glucagon-like
31%
Glucagon-like peptide-1 (GLP-1)
31%
Protein Level
25%
Cardiac Lesions
14%
Lower Body Negative Pressure
14%
Reduced LVEF
14%
Sodium Chloride
10%
Physical Stressors
10%
Dysmetabolic
10%
Long-term Control
10%
Left Ventricular Apical Ballooning
10%
Blood Pressure Level
10%
Bleeding History
9%
Bleeding Risk
9%
Heterogeneous Patients
8%
Risk Factors
8%
Serum Creatinine
8%
Medicine and Dentistry
Heart Failure
100%
Acute Kidney Injury
84%
Percutaneous Coronary Intervention
84%
Amino Terminal Sequence
60%
Brain Natriuretic Peptide
60%
Acute Decompensated Heart Failure
50%
Creatinine
47%
Ischemic Heart Disease
42%
Bone Density
42%
Mobilization
42%
Omecamtiv Mecarbil
42%
Adverse Outcome
42%
Coronary Artery
42%
Diagnostic Accuracy
42%
Heart Failure with Preserved Ejection Fraction
42%
Urinary System
42%
D-Dimer
42%
Heart Failure with Reduced Ejection Fraction
42%
Intensive Care Unit
42%
Rosuvastatin
42%
Rhabdomyolysis
42%
Protein Z
42%
Proteinuria
42%
Chronic Total Occlusion
42%
Fluoroscopy
28%
Proportional Hazards Model
22%
Renin
21%
microRNA 223
21%
Heart Left Ventricle Ejection Fraction
21%
Warfarin
17%
Intercostal Space
16%
ST Elevation
16%
Survival Rate
14%
Heart Muscle Ischemia
8%
Transluminal Coronary Angioplasty
8%
Chronic Kidney Disease
8%
Nephropathy
8%
Left Anterior Descending Coronary Artery
8%
Recanalization
8%
Disease
8%
Cause of Death
8%
Sensitivity and Specificity
8%
Risk Stratification
8%
Myocardial Infarction
8%
Artery Lesion
8%
Right Coronary Artery
8%
Acute Coronary Syndrome
8%
Electrocardiographic Finding
8%
Kidney Transplantation
8%
Renal Replacement Therapy
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Heart Failure
50%
Omecamtiv Mecarbil
42%
D Dimer
42%
Heart Failure with Preserved Ejection Fraction
42%
Heart Failure with Reduced Ejection Fraction
42%
Fatty Acid Binding Protein
42%
Atrial Fibrillation
42%
Rhabdomyolysis
42%
Rosuvastatin
42%
Creatinine
42%
Azilsartan
42%
Brain Natriuretic Peptide
42%
Hydrochlorothiazide
42%
Thiazide Diuretic Agent
42%
Adverse Outcome
42%
Acute Kidney Failure
42%
Anticoagulant Agent
42%
Candesartan
31%
Resistin
31%
Glucagon-Like Peptide-1
31%
Warfarin
17%
Heart Failure
15%
Essential Hypertension
10%
Bleeding
10%
Acute Coronary Syndrome
8%
Chronic Kidney Failure
8%
Disease
8%
Cause of Death
8%
End Stage Renal Disease
8%
Kidney Disease
8%
Population Study
5%
